ALLMedicine™ Fungal Pneumonia Center
Research & Reviews 53 results
https://doi.org/10.1016/j.rcl.2022.01.006
Radiologic Clinics of North America; Godoy MCB, Ferreira Dalla Pria HR et. al.
May 10th, 2022 - Fungal pneumonia is the most frequent presentation of invasive fungal infections (IFIs) in patients with hematologic malignancies (HM) and hematopoietic stem cell transplantation (HSCT) recipients. The most common causes include Aspergillus, Mucor...
https://clinicaltrials.gov/ct2/show/NCT05037851
May 4th, 2022 - Part 1 of the study comprises a 12 week Prophylaxis or Pre-emptive Therapy Phase. Part 2 comprises a 4-week Safety Follow-Up Phase. The study will screen single or double lung transplant recipients due to receive a mold-active antifungal: either a...
https://doi.org/10.1016/j.imbio.2022.152194
Immunobiology Figuerêdo Moreira I, Marcelino Alvares-Saraiva A et. al.
Mar 13th, 2022 - Opportunistic fungal pneumonia is a cause of concern in immunocompromised patients due to its high morbidity and mortality rates. One such opportunistic agent affecting immunocompromised patients is the microsporidia called Encephalitozoon cunicul...
https://emedicine.medscape.com/article/296198-overview
Oct 12th, 2021 - Overview of Aspiration Pneumonia Aspiration is defined as the inhalation of either oropharyngeal or gastric contents into the lower airways, that is, the act of taking foreign material into the lungs. This can cause a number of syndromes determine...
https://emedicine.medscape.com/article/296198-print
Oct 12th, 2021 - Aspiration is defined as the inhalation of either oropharyngeal or gastric contents into the lower airways, that is, the act of taking foreign material into the lungs. This can cause a number of syndromes determined by the quantity and nature of t...
Clinicaltrials.gov 2 results
https://clinicaltrials.gov/ct2/show/NCT05037851
May 4th, 2022 - Part 1 of the study comprises a 12 week Prophylaxis or Pre-emptive Therapy Phase. Part 2 comprises a 4-week Safety Follow-Up Phase. The study will screen single or double lung transplant recipients due to receive a mold-active antifungal: either a...
https://clinicaltrials.gov/ct2/show/NCT03793231
Oct 23rd, 2020 - Invasive fungal diseases (IFD) are rare infections that cause a life-threatening pneumonia in patients with weakened immune systems usually due to cancer chemotherapy and transplantation. Fungal spores are found in air, water and soil making expos...
News 13 results
https://www.onclive.com/view/fda-approves-brexucabtagene-autoleucel-for-relapsed-refractory-b-all
Oct 8th, 2021 - The FDA has approved brexucabtagene autoleucel (Tecartus; formerly KTE-X19) as a treatment for adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (B-ALL).1 The regulatory decision was based on findings from the ...
https://www.onclive.com/view/fda-grants-car-t-cell-therapy-allo-715-orphan-drug-status-for-multiple-myeloma
Aug 17th, 2021 - The FDA has granted an orphan drug designation to the allogeneic CAR T-cell therapy ALLO-715 for the treatment of patients with multiple myeloma, according to an announcement from Allogene Therapeutics, Inc., the drug developer.1 Data from the ...
https://www.onclive.com/view/kte-x19-induces-high-durable-response-rate-in-heavily-pretreated-relapsed-refractory-b-all
Jun 5th, 2021 - A single infusion of brexucabtagene autoleucel (formerly KTE-X19; Tecartus), a CAR T-cell therapy, demonstrated robust and durable responses in heavily pretreated patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL), accor...
https://www.onclive.com/view/fda-grants-rmat-designation-to-allo-715-for-relapsed-refractory-multiple-myeloma
Apr 21st, 2021 - The FDA granted a Regenerative Medicine Advanced Therapy (RMAT) designation to the allogeneic chimeric antigen receptor (CAR) T-cell therapy as a potential treatment for patients with relapsed/refractory multiple myeloma, according to Allogene The...
https://www.onclive.com/view/the-importance-of-supportive-care-in-aml
Apr 2nd, 2021 - Transcript:Ruben A. Mesa, MD, FACP: Elias, you brought up earlier an excellent point and a segue into our last key section on the issue of support infection and all other aspects. And we’ve had a good discussion regarding how there’s been signific...
